You are here

Otzela

The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023

BioSpace

Wed, 08/23/23 - 11:11 am

Eiger Pharmaceuticals

Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster

Fierce Biotech

Thu, 10/7/21 - 11:24 am

Bristol Myers Squibb

deucravacitinib

ulcerative colitis

Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals

Fierce Pharma

Wed, 07/29/20 - 12:31 pm

Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win

Motley Fool

Mon, 08/26/19 - 10:56 pm

FDA Approves First Treatment for Oral Ulcers Associated with Rare Inflammatory Disease

BioSpace

Mon, 07/22/19 - 11:41 am

Behcet's disease